Cargando…
Antistaphylococcal activity of bacteriophage derived chimeric protein P128
BACKGROUND: Bacterial drug resistance is one of the most significant challenges to human health today. In particular, effective antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) are urgently needed. A causal relationship between nasal commensal S. aureus and infection h...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362776/ https://www.ncbi.nlm.nih.gov/pubmed/22439788 http://dx.doi.org/10.1186/1471-2180-12-41 |
_version_ | 1782234258691063808 |
---|---|
author | Vipra, Aradhana A Desai, Srividya Narayanamurthy Roy, Panchali Patil, Raghu Raj, Juliet Mohan Narasimhaswamy, Nagalakshmi Paul, Vivek Daniel Chikkamadaiah, Ravisha Sriram, Bharathi |
author_facet | Vipra, Aradhana A Desai, Srividya Narayanamurthy Roy, Panchali Patil, Raghu Raj, Juliet Mohan Narasimhaswamy, Nagalakshmi Paul, Vivek Daniel Chikkamadaiah, Ravisha Sriram, Bharathi |
author_sort | Vipra, Aradhana A |
collection | PubMed |
description | BACKGROUND: Bacterial drug resistance is one of the most significant challenges to human health today. In particular, effective antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) are urgently needed. A causal relationship between nasal commensal S. aureus and infection has been reported. Accordingly, elimination of nasal S. aureus reduces the risk of infection. Enzymes that degrade bacterial cell walls show promise as antibacterial agents. Bacteriophage-encoded bacterial cell wall-degrading enzymes exhibit intrinsic bactericidal activity. P128 is a chimeric protein that combines the lethal activity of the phage tail-associated muralytic enzyme of Phage K and the staphylococcal cell wall targeting-domain (SH3b) of lysostaphin. Here we report results of in vitro studies evaluating the susceptibility of staphylococcal strains to this novel protein. RESULTS: Using the broth microdilution method adapted for lysostaphin, we found that P128 is effective against S. aureus clinical strains including MRSA, methicillin-sensitive S. aureus (MSSA), and a mupirocin-resistant S. aureus. Minimum bactericidal concentrations and minimum inhibitory concentrations of P128 (1-64 μg/mL) were similar across the 32 S. aureus strains tested, demonstrating its bactericidal nature. In time-kill assays, P128 reduced colony-forming units by 99.99% within 1 h and inhibited growth up to 24 h. In an assay simulating topical application of P128 to skin or other biological surfaces, P128 hydrogel was efficacious when layered on cells seeded on solid media. P128 hydrogel was lethal to Staphylococci recovered from nares of healthy people and treated without any processing or culturing steps, indicating its in situ efficacy. This methodology used for in vitro assessment of P128 as an agent for eradicating nasal carriage is unique. CONCLUSIONS: The novel chimeric protein P128 is a staphylococcal cell wall-degrading enzyme under development for clearance of S. aureus nasal colonization and MRSA infection. The protein is active against globally prevalent antibiotic-resistant clinical isolates and other clinically significant staphylococcal species including S. epidermidis. The P128 hydrogel formulation was bactericidal against Staphylococci including S. aureus recovered from the nares of 31 healthy people, demonstrating its in situ efficacy. |
format | Online Article Text |
id | pubmed-3362776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33627762012-05-31 Antistaphylococcal activity of bacteriophage derived chimeric protein P128 Vipra, Aradhana A Desai, Srividya Narayanamurthy Roy, Panchali Patil, Raghu Raj, Juliet Mohan Narasimhaswamy, Nagalakshmi Paul, Vivek Daniel Chikkamadaiah, Ravisha Sriram, Bharathi BMC Microbiol Research Article BACKGROUND: Bacterial drug resistance is one of the most significant challenges to human health today. In particular, effective antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) are urgently needed. A causal relationship between nasal commensal S. aureus and infection has been reported. Accordingly, elimination of nasal S. aureus reduces the risk of infection. Enzymes that degrade bacterial cell walls show promise as antibacterial agents. Bacteriophage-encoded bacterial cell wall-degrading enzymes exhibit intrinsic bactericidal activity. P128 is a chimeric protein that combines the lethal activity of the phage tail-associated muralytic enzyme of Phage K and the staphylococcal cell wall targeting-domain (SH3b) of lysostaphin. Here we report results of in vitro studies evaluating the susceptibility of staphylococcal strains to this novel protein. RESULTS: Using the broth microdilution method adapted for lysostaphin, we found that P128 is effective against S. aureus clinical strains including MRSA, methicillin-sensitive S. aureus (MSSA), and a mupirocin-resistant S. aureus. Minimum bactericidal concentrations and minimum inhibitory concentrations of P128 (1-64 μg/mL) were similar across the 32 S. aureus strains tested, demonstrating its bactericidal nature. In time-kill assays, P128 reduced colony-forming units by 99.99% within 1 h and inhibited growth up to 24 h. In an assay simulating topical application of P128 to skin or other biological surfaces, P128 hydrogel was efficacious when layered on cells seeded on solid media. P128 hydrogel was lethal to Staphylococci recovered from nares of healthy people and treated without any processing or culturing steps, indicating its in situ efficacy. This methodology used for in vitro assessment of P128 as an agent for eradicating nasal carriage is unique. CONCLUSIONS: The novel chimeric protein P128 is a staphylococcal cell wall-degrading enzyme under development for clearance of S. aureus nasal colonization and MRSA infection. The protein is active against globally prevalent antibiotic-resistant clinical isolates and other clinically significant staphylococcal species including S. epidermidis. The P128 hydrogel formulation was bactericidal against Staphylococci including S. aureus recovered from the nares of 31 healthy people, demonstrating its in situ efficacy. BioMed Central 2012-03-22 /pmc/articles/PMC3362776/ /pubmed/22439788 http://dx.doi.org/10.1186/1471-2180-12-41 Text en Copyright ©2012 Vipra et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Vipra, Aradhana A Desai, Srividya Narayanamurthy Roy, Panchali Patil, Raghu Raj, Juliet Mohan Narasimhaswamy, Nagalakshmi Paul, Vivek Daniel Chikkamadaiah, Ravisha Sriram, Bharathi Antistaphylococcal activity of bacteriophage derived chimeric protein P128 |
title | Antistaphylococcal activity of bacteriophage derived chimeric protein P128 |
title_full | Antistaphylococcal activity of bacteriophage derived chimeric protein P128 |
title_fullStr | Antistaphylococcal activity of bacteriophage derived chimeric protein P128 |
title_full_unstemmed | Antistaphylococcal activity of bacteriophage derived chimeric protein P128 |
title_short | Antistaphylococcal activity of bacteriophage derived chimeric protein P128 |
title_sort | antistaphylococcal activity of bacteriophage derived chimeric protein p128 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362776/ https://www.ncbi.nlm.nih.gov/pubmed/22439788 http://dx.doi.org/10.1186/1471-2180-12-41 |
work_keys_str_mv | AT vipraaradhanaa antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT desaisrividyanarayanamurthy antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT roypanchali antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT patilraghu antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT rajjulietmohan antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT narasimhaswamynagalakshmi antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT paulvivekdaniel antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT chikkamadaiahravisha antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 AT srirambharathi antistaphylococcalactivityofbacteriophagederivedchimericproteinp128 |